Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Annovis Bio Inc. (NYSE: ANVS) announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1, 2024. The presentations will highlight the progress of buntanetap, the company's drug candidate for neurodegenerative disorders like Alzheimer's and Parkinson's disease.
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present two posters:
- Poster LP023: 'Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer's Patients'
- Poster LP074: 'Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer's Clinical Studies'
The posters will be available on Annovis' website after the conference concludes.
Annovis Bio Inc. (NYSE: ANVS) ha annunciato che presenterà due poster scientifici al 17° Congresso sui Trials Clinici sulla Malattia di Alzheimer (CTAD) che si terrà a Madrid, Spagna, dal 29 ottobre al 1 novembre 2024. Le presentazioni mostreranno i progressi di buntanetap, il candidato farmaco dell'azienda per i disturbi neurodegenerativi come la malattia di Alzheimer e il Parkinson.
La Dr.ssa Maria Maccecchini, Presidente e CEO di Annovis Bio, presenterà due poster:
- Poster LP023: 'Efficacia di Buntanetap in pazienti AD precoci e di fase 2/3 APOE4'
- Poster LP074: 'I dati sui biomarker hanno mostrato che Buntanetap ha ridotto le proteine neurotossiche, ha migliorato l'integrità assonale, ha ridotto l'infiammazione e le funzioni neuronali negli studi clinici sulla malattia di Alzheimer'
I poster saranno disponibili sul sito web di Annovis dopo la conclusione della conferenza.
Annovis Bio Inc. (NYSE: ANVS) anunció que presentará dos carteles científicos en la 17ª Conferencia sobre Ensayos Clínicos en la Enfermedad de Alzheimer (CTAD) que se llevará a cabo en Madrid, España, del 29 de octubre al 1 de noviembre de 2024. Las presentaciones destacarán los avances de buntanetap, el candidato a fármaco de la compañía para trastornos neurodegenerativos como la enfermedad de Alzheimer y de Parkinson.
La Dra. Maria Maccecchini, Presidenta y CEO de Annovis Bio, presentará dos carteles:
- Cartel LP023: 'Eficacia de Buntanetap en pacientes con AD temprana y APOE4 en fase 2/3'
- Cartel LP074: 'Los datos de biomarcadores mostraron que Buntanetap redujo proteínas neurotóxicas, mejoró la integridad axonal, redujo la inflamación y mejoró las funciones neuronales en estudios clínicos sobre Alzheimer'
Los carteles estarán disponibles en el sitio web de Annovis tras la conclusión de la conferencia.
Annovis Bio Inc. (NYSE: ANVS)는 2024년 10월 29일부터 11월 1일까지 스페인 마드리드에서 열리는 제17회 알츠하이머병에 대한 임상시험(CTAD) 회의에서 두 개의 과학 포스터를 발표할 것이라고 발표했습니다. 발표는 알츠하이머병과 파킨슨병과 같은 신경퇴행성 질환을 위한 회사의 약물 후보인 buntanetap의 발전을 강조합니다.
Annovis Bio의 사장 겸 CEO인 마리아 마체키니 박사는 두 개의 포스터를 발표할 예정입니다:
- 포스터 LP023: '초기 AD 및 APOE4 2/3상 알츠하이머 환자에서의 Buntanetap의 효능'
- 포스터 LP074: '생물표지 데이터는 Buntanetap이 신경독성 단백질을 감소시키고 축삭 무결성을 개선했으며 염증과 신경 기능을 감소시켰음을 보여주었습니다. 알츠하이머 임상 연구에서'
포스터는 회의 종료 후 Annovis 웹사이트에서 확인할 수 있습니다.
Annovis Bio Inc. (NYSE: ANVS) a annoncé qu'il présentera deux affiches scientifiques lors de la 17ème Conférence sur les Essais Cliniques de la Maladie d'Alzheimer (CTAD) qui se tiendra à Madrid, Espagne, du 29 octobre au 1 novembre 2024. Les présentations mettront en lumière les progrès de buntanetap, le candidat médicament de l'entreprise pour les troubles neurodégénératifs tels que la maladie d'Alzheimer et de Parkinson.
Dr. Maria Maccecchini, Présidente et CEO d'Annovis Bio, présentera deux affiches :
- Affiche LP023 : 'Efficacité de Buntanetap chez les patients AD précoces et APOE4 en phase 2/3'
- Affiche LP074 : 'Les données de biomarqueurs ont montré que Buntanetap a réduit les protéines neurotoxiques, amélioré l'intégrité axonale, réduit l'inflammation et amélioré les fonctions neuronales dans les études cliniques sur Alzheimer'
Les affiches seront disponibles sur le site web d'Annovis après la fin de la conférence.
Annovis Bio Inc. (NYSE: ANVS) hat angekündigt, dass es zwei wissenschaftliche Poster auf der 17. Konferenz zu klinischen Studien über Alzheimer (CTAD) präsentieren wird, die vom 29. Oktober bis 1. November 2024 in Madrid, Spanien, stattfindet. Die Präsentationen werden die Fortschritte von buntanetap, dem Wirkstoffkandidaten des Unternehmens für neurodegenerative Erkrankungen wie Alzheimer und Parkinson, hervorheben.
Dr. Maria Maccecchini, Präsidentin und CEO von Annovis Bio, wird zwei Poster präsentieren:
- Poster LP023: 'Wirksamkeit von Buntanetap bei frühen AD- und APOE4-Phase-2/3-Alzheimer-Patienten'
- Poster LP074: 'Biomarker-Daten zeigen, dass Buntanetap neurotoxische Proteine reduzierte, axonale Integrität verbesserte, Entzündungen verringerte und neuronale Funktionen in klinischen Studien zur Alzheimerkrankheit verbesserte'
Die Poster werden nach Abschluss der Konferenz auf der Website von Annovis verfügbar sein.
- Annovis Bio will present research progress on buntanetap at a major Alzheimer's disease conference
- The company's drug candidate shows potential efficacy in early Alzheimer's and APOE4 patients
- Biomarker data indicates multiple positive effects of buntanetap in Alzheimer's studies
- None.
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain.
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present the following posters:
Poster LP023
Title: Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients.
Date: Tuesday, October 29, 3:00 PM – Wednesday, October 30, 5:00 PM (CET).
Poster LP074
Title: Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies.
Date: Thursday, October 31, 7:15 AM – 5:00 PM (CET).
The posters will be available on Annovis’ website following the conclusion of the conference.
About CTAD 2024
CTAD 2024 brings together leaders from the Alzheimer’s research community, including pharmaceutical companies, academic research centers, and patient advocacy groups. The conference serves as a platform for discussing innovative avenues for the treatment of Alzheimer’s disease.
For more information about the conference, please visit the CTAD Website.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
What will Annovis Bio (ANVS) present at the CTAD 2024 conference?
When and where will the CTAD 2024 conference take place?
What is buntanetap and what is it being developed for by Annovis Bio (ANVS)?
Who will present Annovis Bio's (ANVS) posters at CTAD 2024?
